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a  b  s  t  r  a  c  t
BCG  revaccination  is  still  used  in  some  tuberculosis  endemic  countries.  Until  now,  the  little  evidence
available  suggested  that  BCG revaccination  confers  very  limited  additional  protection,  although  there  was
no  information  on  whether  protection  depends  on  the setting  and  age  of revaccination,  or  if protection
increases  with  time  since  vaccination.  Here  we  report  on  an  extended  follow  up  of the  BCG-REVAC  trial,
a  cluster  randomised  trial conducted  in the  Brazilian  cities  Salvador  and  Manaus  including  over  200,000
children  aged  7–14  years  aimed  to evaluate  the  efﬁcacy  of  BCG  revaccination  in children  who  had  received
neonatal  BCG  vaccination.  With  the  extended  follow-up  (9 years)  and  the  additional  cases  accrued  we
now  have  enough  power  to report  vaccine  efﬁcacy  separately  for  the  two  cities  (with  different  distances
from  Equator  and  presumably  different  prevalence  of  non-tuberculosis  mycobacteria),  and  by age  atevaccination
chool  age
vaccination  and  clinical  form.  The  overall  vaccine  efﬁcacy  was  12%  (−2 to  24%)  as compared  to 9%  (−16 to
29%)  for  the  5-year  follow  up.  Vaccine  efﬁcacy  was  higher  in  Salvador  (19%,  3 to  33%) than  in  Manaus  (1%,
−27  to  27%)  with  the  highest  vaccine  efﬁcacy  in  children  from  Salvador  aged  <11  years  at  revaccination
(33%,  3 to 54%).  The  ﬁndings  are in  line  with  the  hypothesis  that  BCG vaccination  offers  higher  efﬁcacy
in  low  NTMb  prevalence,  and  show  that revaccination  with  BCG  can  offer  weak  protection  in selected
subgroups.. Introduction
Tuberculosis (tb) is one of the leading causes of death in the
eveloping world [1]. BCG vaccination in the ﬁrst year of life offers
xcellent protection against extra pulmonary forms of tuberculosis
EPTB) in childhood [2] but protection from pulmonary tubercu-
osis (PTB) varies from 0 to 80% [3]. WHO  recommends neonatal
CG vaccination [4] which is routine in many countries [5]. The
vidence so far suggested that revaccination confers no additional
rotection to neonatal vaccination. In Malawi, a trial of the effect
f a second BCG vaccination in children and adults showed no pro-
ection against tuberculosis [6]. The BCG REVAC trial focusing on
chool aged children, conducted in Brazil and reported in 2005
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also showed no additional protection of a second BCG vaccina-
tion against tuberculosis (VE 9% (−16 to 29%)) or leprosy [7,8]. It is
not known whether protection given by a second BCG vaccination
would vary according to the setting or the age at revaccination; or if
protection will be higher with longer follow up after revaccination.
After an additional 4 years of follow up, the BCG REVAC trial has
now increased power to detect differences in the vaccine efﬁcacy
between different settings and age groups.
2. Material and methods
The  BCG-REVAC cluster randomised trial had the objective to
estimate the vaccine efﬁcacy of BCG revaccination. The number
Open access under the Elsevier OA license.of cases during the ﬁrst 5 years of follow up was  too small to
allow subgroup analyses [7]. However, the 486 cases accrued from
an additional 4 years of follow up now provide sufﬁcient power
for more detailed analyses. A description of the study design [9],
4 ccine 29 (2011) 4875– 4877
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alidity of scar reading [10] and adverse events were presented
lsewhere [11]. Brieﬂy, the BCG-REVAC trial was conducted in two
razilian cities: Salvador and Manaus. One of the reasons offered
or the variation in BCG efﬁcacy is variations in prevalence of non-
uberculosis mycobacteria, which is correlated to latitude [12]. The
ities were chosen to make it possible to investigate whether BCG
accine efﬁcacy is different in cities with different latitudes [12].
anaus is situated near the Equator with a high temperature and
umidity and presumably a high prevalence of non-tuberculosis
ycobacteria (NTMb)[13]; Salvador lies further away from the
quator and has a low prevalence of NTMb. Stratiﬁed randomi-
ation (with strata of similar socio-economic characteristics and
ncidence of tuberculosis/leprosy) was used to allocate 763 schools
o intervention arm and control arm. In each arm children’s BCG
accination status was assessed by BCG scar reading and baseline
nformation was collected. The study population to assess the efﬁ-
acy of revaccination consisted of children aged 7–14 years with
ne BCG scar only before revaccination (n = 200,805 children). In
he intervention arm 103,718 children were vaccinated with the
oreaux strain (Rio de Janeiro); 97,087 children received no inter-
ention and formed the controlled group. The trial was open-label
ith no placebo. Participants were able to “opt out” – i.e.  parents
f children in schools allocated to the intervention arm were given
nformation about the trial and the vaccination and could withdraw
heir children. Details of the study population and the recruitment
rocess have been described previously [7].
We identiﬁed cases via the Brazilian Tuberculosis Control Pro-
ramme, the only provider of tuberculosis treatment in Brazil. Cases
ere validated by independent physicians and linked to the study
opulation.
The incidence of tuberculosis was the primary outcome.
e used a Poisson regression based on generalised-estimating-
quations  (GEE) suitable for overdispersed data [14] to calculate
he incidence rate ratio (IRR) and calculated vaccine efﬁcacy as
1 − [rate of tb amongst vaccinated/rate of tb amongst unvaccinated
hildren]) × 100. Calculation of the IRR was controlled for socio-
conomic status, incidence of tuberculosis and leprosy, sex, age at
accination and age at diagnosis. Age at diagnoses was modelled as
 time-dependent variable.
The  ethics committee of the University Hospital, Univer-
idade Federal da Bahia and the ethics committee of the
ondon School of Hygiene and Tropical Medicine approved
he trial. The trial is registered with an International Stan-
ard Randomised Controlled Trial Number, ISRCTN07601391
http://www.controlled-trials.com/ISRCTN07601391).
. Results
These are the results of the 9-year follow up of children re-
accinated at school age. Baseline data on the individual and cluster
haracteristics and children excluded from the analysis have been
escribed previously [7].
There  were 765 cases of tuberculosis in this analysis: 378 in the
ntervention group and 387 in the control group, a higher incidence
han in previous years given the increase in incidence of tuber-
ulosis in young adults. Table 1 shows the number of pulmonary
nd non-pulmonary tuberculosis cases by age of vaccination and
y study site.
The  estimated number of person years of follow up was
,806,558; 933,107 in the intervention and 873,451 in the control
roup. The crude incidence of tuberculosis was 41.6 per 100,000
erson years in the intervention group and 45.5 per 100,000 per-
on years in the control group (Rate ratio 0.91, 0.79–1.05). There
as no evidence for a design effect when comparing parameters
etween the naïve and the GEE regression model. Ta
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Table 1 shows the vaccine efﬁcacy (VE) according to study site
nd age at diagnosis. Revaccination was protective in Salvador (VE
9%, 3–33%) but not in Manaus (VE 1%, −27 to 23%). In Salvador only
hildren aged <11 years at vaccination where protected (VE 33%,
–54%). For both cities combined, weak evidence of a protective
ffect was found (p = 0.08); although the combined measure is of
ifﬁcult interpretation.
.  Discussion
Efﬁcacy of BCG revaccination presented a small not signif-
cant increase with time of follow up, from 9% (−16 to 29%)
t 0–5 years of follow up to 12% (−2 to 24%) at 0–9 years
f follow up. Efﬁcacy was almost 20% in Salvador, and practi-
ally zero in Manaus; it was higher when given at younger age.
lthough this ﬁnding could be due to chance considering the
arge and overlapping conﬁdence intervals, it was  unexpected:
e expected efﬁcacy of revaccination to increase with age at
accination as efﬁcacy of neonatal BCG decreases. A possible expla-
ation is that infection with Mycobacterium tuberculosis (M. tb)
ncreases with age. In fact, in the study population from Sal-
ador positive PPD results increased from 14.5% in children aged
–8 years to 28% in children aged 13–14 years [15].
The difference in VE between the two cities was in the direction
xpected, based on the fact that Manaus is closer to the Equa-
or and presumably has higher prevalence of M.  tb and NTMb [3].
ifferent infection rates with M.  tb prior to revaccination could
lso explain the different vaccine efﬁcacies between the study
ites. Infection with M.  tb. reduces the protective effect of the BCG
accine [12].
The  follow up of this trial will continue to accrue power to
onﬁrm the effect modiﬁcation by city and age at vaccination,
nd detect differences in the vaccine efﬁcacy for PTB and EPTB.
egarding the overall vaccine efﬁcacies, however, it seems that
CG revaccination confers a similar protection on the two different
linical forms of tuberculosis.
.  Conclusions
An additional 4 years of follow up of children revaccinated with
CG at school age showed that revaccination can offer additional
rotection, although protection was restricted to Salvador, the site
urther from the Equator, and conﬁned to a small subgroup of chil-
ren aged <11 years at vaccination.
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